Scinai Competitors
| SCNI Stock | USD 0.85 0.06 6.73% |
Scinai Immunotherapeuti vs Enveric Biosciences Correlation
Very weak diversification
The correlation between Scinai Immunotherapeutics and ENVB is 0.56 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Scinai Immunotherapeutics and ENVB in the same portfolio, assuming nothing else is changed.
Moving together with Scinai Stock
Moving against Scinai Stock
| 0.44 | FCAP | First Capital Normal Trading | PairCorr |
| 0.42 | BNKHF | BOC Hong Kong | PairCorr |
| 0.38 | OBYCF | Obayashi Earnings Call This Week | PairCorr |
| 0.37 | GGLDF | Getchell Gold Corp | PairCorr |
Scinai Immunotherapeuti Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Scinai Immunotherapeuti and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Scinai and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Scinai Immunotherapeutics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Scinai Stock performing well and Scinai Immunotherapeuti Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Scinai Immunotherapeuti's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ONCO | 4.94 | (1.33) | 0.00 | 5.21 | 0.00 | 9.09 | 36.81 | |||
| SPRC | 4.17 | (2.27) | 0.00 | (3.76) | 0.00 | 3.57 | 30.69 | |||
| AZTR | 4.93 | (0.99) | 0.00 | (1.33) | 0.00 | 7.14 | 36.11 | |||
| INDP | 5.97 | (0.69) | 0.00 | (0.19) | 0.00 | 13.58 | 51.64 | |||
| SLXN | 4.12 | (0.91) | 0.00 | (0.39) | 0.00 | 15.09 | 37.24 | |||
| SLRX | 6.68 | (1.91) | 0.00 | 4.47 | 0.00 | 16.00 | 61.05 | |||
| JSPR | 4.21 | (0.54) | 0.00 | 9.79 | 0.00 | 7.73 | 31.75 | |||
| REVB | 3.88 | (1.67) | 0.00 | (0.88) | 0.00 | 6.12 | 35.57 | |||
| PBM | 7.66 | (3.78) | 0.00 | (0.60) | 0.00 | 9.41 | 96.64 | |||
| ENVB | 7.19 | (0.56) | 0.00 | (0.13) | 0.00 | 14.08 | 121.83 |
Cross Equities Net Income Analysis
Compare Scinai Immunotherapeutics and related stocks such as Onconetix, Scisparc, and Azitra Inc Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ONCO | (821.9 K) | (821.9 K) | (821.9 K) | (821.9 K) | (821.9 K) | (821.9 K) | (821.9 K) | (821.9 K) | (821.9 K) | (821.9 K) | (1.6 M) | (3.4 M) | (13.4 M) | (37.4 M) | (58.7 M) | (52.8 M) | (50.2 M) |
| SPRC | (1.7 M) | (3.7 M) | (3.5 M) | 59.4 K | (1.9 M) | (2.5 M) | (2 M) | (6.2 M) | (8.5 M) | (5.4 M) | (3.5 M) | (5.8 M) | (2.6 M) | (5.1 M) | (6.3 M) | (5.7 M) | (5.9 M) |
| AZTR | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (10.7 M) | (11.3 M) | (9 M) | (8.1 M) | (8.5 M) |
| INDP | (5.4 M) | (7.6 M) | (5.2 M) | (5.1 M) | (5.7 M) | (7.2 M) | (13.4 M) | (28.9 M) | (43.5 M) | (47.6 M) | (3.6 M) | (7.7 M) | (14.3 M) | (15.4 M) | (15 M) | (13.5 M) | (14.2 M) |
| SLXN | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (755.2 K) | (3.2 M) | (4.9 M) | (16.4 M) | (14.8 M) | (14.1 M) |
| JSPR | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (31.7 M) | (30.6 M) | (37.7 M) | (64.5 M) | (71.3 M) | (64.1 M) | (67.3 M) |
| REVB | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 6.2 M | 8.8 M | 16.3 M | 27.6 M | (3.6 K) | (136.4 K) | (12 M) | (10.8 M) | (120.3 K) | (15 M) | (13.5 M) | (12.9 M) |
| PBM | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8 M | (51.2 M) | 1 M | 910.6 K | 956.1 K |
| ENVB | (1.2 M) | (33.4 K) | (24.6 K) | (161) | (33.6 K) | (1.9 M) | (2.8 M) | (9.1 M) | (16.9 M) | (5.6 M) | (6.9 M) | (49 M) | (18.5 M) | (17.3 K) | (9.6 M) | (8.6 M) | (8.2 M) |
Scinai Immunotherapeutics and related stocks such as Onconetix, Scisparc, and Azitra Inc Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Scinai Immunotherapeutics financial statement analysis. It represents the amount of money remaining after all of Scinai Immunotherapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Scinai Immunotherapeuti Competitive Analysis
The better you understand Scinai Immunotherapeuti competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Scinai Immunotherapeuti's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Scinai Immunotherapeuti's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Scinai Immunotherapeuti Competition Performance Charts
Five steps to successful analysis of Scinai Immunotherapeuti Competition
Scinai Immunotherapeuti's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Scinai Immunotherapeutics in relation to its competition. Scinai Immunotherapeuti's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Scinai Immunotherapeuti in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Scinai Immunotherapeuti's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Scinai Immunotherapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Scinai Immunotherapeuti position
In addition to having Scinai Immunotherapeuti in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Energy ETFs Thematic Idea Now
Energy ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Energy ETFs theme has 100 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Energy ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Scinai Immunotherapeuti Correlation with its peers. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is there potential for Semiconductors & Semiconductor Equipment market expansion? Will Scinai introduce new products? Factors like these will boost the valuation of Scinai Immunotherapeuti. If investors know Scinai will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Scinai Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.872 | Earnings Share 4 | Quarterly Revenue Growth 0.361 | Return On Assets | Return On Equity |
Understanding Scinai Immunotherapeutics requires distinguishing between market price and book value, where the latter reflects Scinai's accounting equity. The concept of intrinsic value - what Scinai Immunotherapeuti's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Scinai Immunotherapeuti's price substantially above or below its fundamental value.
Please note, there is a significant difference between Scinai Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine if Scinai Immunotherapeuti is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Scinai Immunotherapeuti's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.